Paul Clancy: Lunit and Volpara combined are now one of the largest and most mature AI developers in the world
Paul Clancy, Director of Business Development Europe at Volpara Health, recently shared on LinkedIn:
“Yesterday marked day one of our partnership to conquer cancer together. Lunit and Volpara joining forces will have a huge global impact on breast and lung cancer detection, combined we are now one of the largest and most mature AI developers in the world.
Congratulations to Ralph Highnam for putting in 15+ years of grit in founding and building Volpara and Teri Thomas for leading us through this new transition and beyond.
A few industry people asked me lately ‘Aren’t you concerned about being acquired?’ The answer was a simple no because when I visited Lunits HQ in Seoul, it felt just like walking into Volpara’s HQ in Wellington. Except with delicious free Korean snacks.
Walking around meeting people I felt the exact same ‘geeky’ and ‘techie’ vibe combined with the same dedication to doing something good with our lives to help clinicians fight cancer. It really could not be a better culture-fit for us both!
For my own role in driving Volpara’s renewed focus on Europe, this really is a dream come true! We now have the leading Breast AI to join our platform and an even larger team of European-based scientists, and business and technical experts to deliver outstanding products and customer success to our European clients. All backed with the support of over 300+ people in ANZ, Korea, and the USA.
I think in particular our combined focus on customer success and our longevity is a huge differentiator to many other AI companies. We don’t just install and run; having to quickly chase the next deal to survive, that being the reality of earlier-stage startups. We stick around for the long haul and have a team of experts who stay with the customer for the lifetime of our journey together.
The future is personalizing health screening for everyone, helping radiologists and radiographers deal with ever-increasing worklists, and making sure the ever-scarcer resources in radiology and oncology are used more effectively. Lunit + Volpara are perfectly poised to lead that transition.
If you are attending UKIO in Liverpool in June please come visit our combined booth!”
Source: Paul Clancy/LinkedIn